The NeurologyLive® movement disorders clinical focus page is a source for all the latest news regarding the clinical care of patients with Parkinson disease, essential tremor, Huntington disease, dystonia, ataxia, and more. This page features podcasts, videos, and news about FDA actions, study and clinical trial findings, clinical guideline updates, and interviews with experts in the clinical care of movement disorders.
Check out some of NeurologyLive®'s featured content in the carousel below.
Supernus Issued CRL for Continuous Apomorphine Infusion in Parkinson Disease
October 10th 2022The NDA for the Supernus therapy, supported by data from the phase 3 TOLEDO study in patients with Parkinson disease, will require additional information and 6 months of further review. No additional efficacy or safety studies are required.
Combination of Biomarkers Associated with Stronger Predictions of Progression in Parkinson Disease
October 8th 2022Findings from a study on Parkinson disease revealed that combining blood biomarkers in addition with clinical measures with prognostics modelling are associated with a more vital prediction in disease progression.
NeurologyLive® Brain Games: October 2, 2022
October 2nd 2022Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology, related to the recent 4th Annual International Congress on the Future of Neurology®.
NeurologyLive® Brain Games: September 25, 2022
September 25th 2022Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Association of Neuromuscular & Electrodiagnostic Medicine.
Several Genetic Loci Show Increased Risk of Mortality, Cognitive Impairment in Parkinson Disease
September 19th 2022One of the identified loci related to clinical progression in Parkinson disease expresses ADORA2A in the cerebellum, which encodes the adenosine A2A receptor, a promising target for therapeutics in PD.
WHO’s 6 Action Steps to Address Parkinson Disease Disparities Globally
September 18th 2022Nicoline Schiess, MD, MPH, and colleagues offer insight into the recent publication of the World Health Organization’s 6 action steps aimed at addressing global disparities in individuals with Parkinson disease.
Celebrating the Expansion and Stressing the Importance of Newborn Screening
September 17th 2022The explosion of new science and legislative decisions have expanded the capabilities and reach of newborn screening, providing thousands of families every year an opportunity to seek early, and critical, care for their infants.
Remote Yoga Program Feasible and Benefits Individuals with Functional Neurological Disorder
September 17th 2022Danielle Kipnis, MA, of Columbia University, discussed key components of a yoga program for individuals with functional neurological disorder and from the evaluation, found it feasibility as an intervention.
Future Implications, Outlook of New CDC Developmental Milestone Guidelines: Paul Lipkin, MD
September 13th 2022The director of medical outpatient services at the Kennedy Krieger Institute discussed the long-term effects of the updated developmental milestone guidelines and the need to judge children based on the 75th percentile. [WATCH TIME: 7 minutes]